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Background: The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in cystic ﬁbrosis (CF) patients has increased and MRSA
seems to be associated with a poorer prognosis. The aim of this study was to assess the prevalence and clinical consequences of MRSA and
methicillin-susceptible Staphylococcus aureus (MSSA), associated or not associated with Pseudomonas aeruginosa (PA).
Methods: In a retrospective study on 419 sputum producer patients (293 adults and 126 children N7 years of age), we recorded patient
characteristics, lung function, nutritional status, IV antibiotics and hospitalisations, the presence of SA and/or PA and FEV1 decline over 2 years.
Results: SA was found in 72% of the patients: MSSA in 68.2% of children and 48.8% of adults; MRSA in 17.5% of children and 17.8% of adults.
Sixty percent of MRSA patients and 60.4% of MSSA patients also harboured PA. The rate of deterioration of clinical status of the various groups,
as assessed from respiratory function, IV antibiotic courses and hospitalisations, increased in the order: no SA/no PA, MSSA alone, MRSA alone,
MSSA/PA, MRSA/PA, and PA alone. Nutritional status did not differ between groups. Results were roughly similar for children and adults. The
yearly FEV1 decline was signiﬁcantly higher only for MRSA/PA patients (p=0.03) compared to no SA/no PA patients.
Conclusion: Clinical condition of CF patients with MSSA only or MRSA only appeared similar, whereas MRSA/PA patients had more severe
respiratory function than MSSA/PA patients. In CF patients, MRSA might be more deleterious than MSSA only when associated with PA.
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Staphylococcus aureus (SA) is one of the bacteria most
frequently isolated from the airways of patients with cystic
fibrosis (CF) and one of the first microbes to infect the lungs of
patients with CF [1–4]. It is the most prevalent pathogen in CF
children and adolescents and in many cases is later replaced byby Elsevier B.V. All rights reserved.
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remain infected by SA. The prevalence of methicillin-susceptible
Staphylococcus aureus (MSSA) has remained stable, whereas
methicillin-resistant Staphylococcus aureus (MRSA) strains have
become more prevalent, reaching 25.7% in US patients in 2010
[5].
Chronic bronchial colonisation by PA in children [6] and
adults with CF [7] is associated with a worse prognosis. By
contrast, the consequences of SA colonisation on CF outcomes
have been controversial [8]. However, several recent studies have
suggested that MRSA is associated with increased antibiotic use
[9], greater decline in lung function [10] and increased mortality
[11]. Very few studies have assessed the clinical impact of SA
and PA, each one or together [12], and rarely differentiated
between MSSA and MRSA. Nevertheless, Dasenbrook et al.
suggested that MRSA when not co-cultured with PA may be
associated with worse outcomes [10,11].
The aim of our study was to determine the prevalence and
clinical consequences of MSSA and MRSA bronchial colonisa-
tion, alone or associated with PA, in a large paediatric and adult
CF cohort.
2. Patients and methods
2.1. Patients
We report a retrospective cohort study performed from January
1st, 2005 to December 31st, 2006 at two large CF centres affiliated
with Paris Descartes University (Cochin University Hospital for
adults and Necker University Hospital for children). This study
was conducted in accordance with the Declaration of Helsinki and
French law and was approved by the Institutional Review Board
for Medical Research (CCTIRS # 08-370).
Criteria for inclusion were diagnosis of CF (positive sweat
test and/or two CFTR disease-causing mutations), age above
7 years old and capacity of producing sputum. Criteria for
non-inclusion were lung transplanted patients, patients younger
than 7 years old and patients unable to produce sputum.
2.2. Microbiological methods
Identification of SA was confirmed with the Pastorex
Staph-Plus® slide test (Biorad, France) and antimicrobial suscep-
tibility testing was performed by disc diffusion assay on Mueller-
Hinton agar plates or by VITEK® 2 (bioMérieux, France) and
interpreted according to CSLI and French guidelines [13,14].
2.3. Clinical data
Clinical data were extracted from patient files. Demographic
data included sex and age at the beginning of the study.
Genotypes were classified according to the probable effect of
their mutations on CFTR function [15], regardless of clinical
severity as follows: severe genotype (two severe mutations), mild
genotype (at least one mild mutation), or undetermined genotype
(at least one unidentified mutation and no mild mutation). Patients
were classified as having pancreatic insufficiency if faecal elastasewas b200 μg/g or faecal fat was N6 g/day. We also collected data
about diabetes and liver cirrhosis.
At visits at the beginning of the study (in the beginning of
2005), body mass index (BMI) (weight/height2) was calculated
and pulmonary function tests were performed. Forced vital
capacity (FVC) and forced expiratory volume in one second
(FEV1) are expressed as percentages of the predicted value
(% pred.). We also recorded data concerning IV antibiotic courses
and hospitalisations during the year 2005. This allowed a cross
sectional study, looking for differences in clinical variables
associated with the presence of MRSA, MSSA or PA colonisation
alone, or in combination.
We also computed the yearly change in FEV1 (delta FEV1) as
the difference between the value at the index visit and that at the
end of each year (from the beginning of 2005 to the end of 2006).
We compared the decline in FEV1 over a 2-year period in
patients colonised with MRSA or MSSA, alone or in combina-
tion with PA to patients not colonised with SA nor PA.
Results of sputum samples were available one year previous
the beginning of the study and during the two years of the
study. Patients were considered to be chronically colonised
with SA or PA when these organisms were detected in at least
three sputum samples during the previous year. Patients
harbouring both MSSA and MRSA were classified in the
MRSA group. MRSA was considered to be persistent if
detected in more than one year.
2.4. Statistical analysis
Data are reported as means±1 standard deviation or percent-
ages, as appropriate. Baseline characteristics were compared
between groups using χ2 or Fisher's exact tests for categorical
variables and analysis of variance or Kruskal–Wallis tests for
continuous variables, as appropriate. Variables which were
available for each year of the follow-up, whether recorded
(colonisation) or computed (delta FEV1 or absolute difference in
FEV1), were analysed using linear or logistic regressions as
appropriate, and multilevel modelling to account for the clustering
effect of subjects (two measures by subject). Linear regression
models with delta FEV1 as the outcome variable were adjusted for
gender, age at baseline, age at diagnosis of CF, genotype, and
pancreatic insufficiency. Residuals were checked for normality
and found to be reasonably satisfactory. Statistical analyses were
2-sided and pb0.05 was considered to have statistical signif-
icance. Since missing data were very few (always b2%) no
additional procedure was necessary for correcting their effect on
the analysis.
3. Results
3.1. Clinical characteristics of the patients
A total of 419 CF patients were included in the study. Their
clinical characteristics at baseline are reported in Table 1.
All the adult patients were sputum producers and only 14 lung
transplanted adult patients could not be included. Among the
children with CF, 72 were not included in the study as they
Table 1
Baseline characteristics of CF patients.
Number of
patients a
Mean±SD or
percentage
Age (years) 419 23.1±9.8
≥18 years old 293 70%
Sex, male 213/419 51%
Age at diagnosis (years) 402 5.9±9.9
Genotype
Severe 315/419 75%
Mild 74/419 18%
Undetermined 30/419 7%
Pancreatic insufficiency 347/417 83%
CF-related diabetes 86/413 21%
Liver cirrhosis 27/415 6%
BMI (kg/m2) 338 19.2±3.1
FEV1 (% predicted) 379 58±26
FVC (% predicted) 372 71±24
IV antibiotic courses in the previous year 391
Number of courses/year 1.5±2
Number of days/year 24±35
Hospitalisations in the previous year 394
Number/year 0.3±0.7
Number of days/year 4±11
BMI: body mass index.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
IV: intravenous.
a Some denominators are below 419 due to some (scattered) missing data.
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included 70% adults and 30% children, with a mean age of
23.1 years (range 7–65); 75% of the patients had a severe CFTR
genotype with 42% (n=177) being F508del homozygous. Their
mean FEV1 at inclusion was 58.5% of the predicted value. The
mean number of IV antibiotic courses per year was 1.5 (range
0–15) and the mean number of hospitalisations per year was 0.3
(range 0–7).
3.2. Microbiological characteristics of the patients
Bacteriological analysis of sputum was available for 413
patients at the beginning of the study (Table 2): 72% (299
patients) had SA, MRSA was present in 73 patients (24% of the
patients with SA), and the prevalence of MRSA was similar in
adults and children; MSSA was more prevalent in children and
PA in adults. PA associated with SA was observed in 146
patients, i.e. in 60% of the patients colonised with SA (107 of
177 patients with MSSA and 39 of 65 patients with MRSA).
Twenty-three patients harboured both MSSA and MRSA.
A large majority of patients with MRSA (77%) had persistent
colonisation.
3.3. Comparison of the patients according to airway colonisation
with SA alone or both SA and PA
Patients were classified according to their bronchial colonisa-
tion with SA and/or PA (Table 3). Respiratory function, as
assessed from FEV1 and FVC, differed between the groups: it
was least affected in patients with neither SA nor PA, thenpatients with MSSA only, MRSA only, MSSA/PA, MRSA/PA,
and was worst in patients with PA alone. The number of IV
antibiotic courses per year significantly increased between the
groups in the same order. Indeed, no statistically significant
difference for any of these clinical variables was observed
between patients with MRSA only and patients with MSSA only,
as well as between patients with MRSA/PA and PA only.
However, patients with MRSA/PA had poorer clinical condition
than patients with MRSA only (p=0.001 for FEV1 and 0.0004
for yearly IV antibiotic courses) or patients with MSSA/PA (p=
0.005 for FEV1 and 0.003 for yearly IV antibiotic courses).
Patients with MRSA/PA had more hospitalisations than patients
with MRSA only (pb0.04). No difference was observed between
groups for nutritional status.
Results for adults and children were roughly similar (Fig. 1).
Children only tended to have less IV antibiotics than adults
when they were colonised with SA (especially with MRSA)
and/or PA. In adults, FEV1 (% pred.) values were: 74.9±22.6
for the no PA and no SA group, 69.1±24.2 for MSSA alone,
63.2±20.9 for MRSA alone, 55.2±21.8 for MSSA/PA, 44.6±
22.3 for MRSA/PA, and 41.7±10.4 for the PA alone group
(pb0.0001 for trend). A similar trend was observed for FEV1
values for children in the different groups: 99.2±15.8 for the no
PA and no SA group, 85.2±18.8 for MSSA alone, 93.6±30.5
for MRSA alone, 74.3±22.8 for MSSA/PA, 63.3±25.0 for
MRSA/PA, and 60.6±22.4 for PA alone (pb0.0001).
We also compared the percentage of severe CFTR genotype
patients between the different groups of bacterial colonisation;
it was 48% in the no SA/no PA group, 68% in the MSSA alone
group, 81% in the MRSA alone group, 75% in the MSSA/PA
group, 83% in the MRSA/PA group and 82% in the PA alone
group. These differences between groups were not statistically
significant when the no SA/no PA group was excluded.
The yearly decline in FEV1 was statistically significant only
in the MRSA/PA group (Table 4) in comparison with the no
SA/no PA patients. Patients infected with MRSA/PA experi-
enced a decline in FEV1 per year of 0.1% more than that of
non-colonised patients. Patients with persistent MRSA did not
experienced higher decline in FEV1 (p=0.68).4. Discussion
In our 419 patients with CF, 53.9% had chronic bronchial
colonisation with MSSA, 17.4% with MRSA and 66.3% with
PA. MSSA was more prevalent in children and PA in adults, and
the prevalence of MRSA was similar in adults and children. In
France, the prevalence of MRSA increased until the year 2005
(16.2% in the adult population and 11.8% in the paediatric
population) [16], corresponding to our study timeframe. Since
this peak, the prevalence of MRSA has gradually declined
(in 2010, 8% in the whole population, 9.7% in adults and 6% in
children) [17]. The increase in the annual prevalence of MRSA
has become a matter of concern in the USA, reaching 25.3% in
the 2010 CFF Patient Registry [5]. Rates of MRSA are much
lower in most European CF centres [1] but have been increasing
over the last 10 years in many groups.
Table 3
Clinical characteristics of study cohort according to respiratory colonisation with St
(Analysis conducted on 362 patients, excluding those with Achromobacter xylosoxi
No SA/no PA MSSA alone
n (percentage) 17 (4.7) 70 (19.3)
Number of adults/children 10/7 35/35
Respiratory function and nutritional status b
FEV1, % predicted (mean±SD) 81.9±23.3 76.3±23.2
FVC, % predicted (mean±SD) 87.8±20.8 83.5±20.5
BMI, kg/m2 (mean±SD) 20.5±4.6 19.2±3.6
IV antibiotic courses and hospitalisations b
Number of antibiotic IV courses/year
(mean±SD)
0.2±0.6 0.5±1.0
Number of days of antibiotic IV courses/year
(mean±SD)
3.9±8.9 9.2±22.0
Number of hospitalisations/year
(mean±SD)
0 0.2±0.4
Number of days of hospitalisation/year
(mean±SD)
0.7±1.3 1.1±2.9
P values for comparisons between groups (post hoc Wilcoxon Rank-Sum test)
MRSA vs
MSSA
MRSA vs
MSSA/PA
MRSA vs
MRSA/PA
FEV1 NS NS 0.0010
FVC NS NS 0.0034
BMI NS NS NS
Number of antibiotic IV
courses/year
NS NS 0.0004
Number of days of antibiotic IV
courses/year
NS NS 0.0008
Number of hospitalisations/
year
NS NS 0.037
Number of days of
hospitalisation/year
NS NS NS
SA: Staphylococcus aureus, PA: Pseudomonas aeruginosa, MSSA: methicillin-suscep
PA: Pseudomonas aeruginosa, FEV1: Forced expiratory volume in one second, FVC: Fo
a Kruskal–Wallis non-parametric test for comparison of the six groups.
b Values of respiratory function and nutritional status were collected at the beginn
during the year 2005.
Table 2
Bacterial respiratory colonisation in adults and children of the study cohort.
Bacteria in sputum All patients
(n=413)
N (%)
Adults
(n=287)
N (%)
Children
(n=126)
N (%)
p
PA 278 (67) 207 (72) 71 (56) 0.002
MSSA 226 (55) 140 (49) 86 (68) b0.001
MRSA 73 (18) 51 (18) 22 (17.5) NS
H. influenzae 91 (22) 61 (21) 30 (24) NS
S. maltophilia 32 (8) 26 (9) 6 (5) NS
A. xylosoxidans 19 (5) 9 (3) 10 (8) b0.05
B. cepacia 10 (2) 10 (3) 0 b0.05
NTM 21 (5) 17 (6) 4 (3) NS
PA Pseudomonas aeruginosa
MRSA methicillin-resistant Staphylococcus aureus
MSSA methicillin-susceptible Staphylococcus aureus
H. influenzae Haemophilus influenzae
S. maltophilia Stenotrophomonas maltophilia
A. xylosoxidans Achromobacter xylosoxidans
B. cepacia Burkholderia cepacia complex
NTM nontuberculous mycobacteria
NS not statistically significant
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and PA bronchial colonisation, as this information is not available
from the publications of national CF registries. Among patients
with CF participating in a phase 3 clinical trial of aerosolised
tobramycin who had PA at entry, 43.2% were also culture
positive for SA [18]; 36 of 191 SA isolates (18.8%) were found to
beMRSA. In comparison, in our study which took place 10 years
later, 58.6% of the patients with PA also harboured SA (43.0%
MSSA and 15.6%MRSA). In an American CF centre, among 82
patients with MRSA between 2005 and 2007, only 12.2% were
never colonised by PA [19].
The long-term consequences of infection with SA in CF
patients have generally been considered less severe than those of
more aggressive pathogens such as PA [12,20–22], but no
distinction has been made betweenMSSA andMRSA. A growing
concern has emerged in recent years for CF patients harbouring
MRSA, who had lower lung function, higher rates of hospi-
talisation and antibiotic treatment than patients with MSSA only
[9]. In our study, we found that patients with MSSA or MRSA not
associated with PA were similar for respiratory function, rate ofaphylococcus aureus and Pseudomonas aeruginosa.
dans, Burkholderia cepacia complex and nontuberculous mycobacteria).
MRSA alone MSSA/PA MRSA/PA PA alone p a value
26 (7.2) 107 (29.6) 39 (10.8) 103 (28.4)
17/9 66/41 29/10 93/10
72.0±27.3 61.9±23.9 49.2±24.1 43.6±20.4 b0.0001
82.6±21.2 74.0±22.1 63.8±20.7 59.3±22.2 b0.0001
19.3±3.0 18.9±3.0 18.8±2.3 19.1±2.9 NS
0.8±1.9 1.4±2.3 2.5±2.6 2.3±1.7 b0.0001
12.5±33.6 23.3±43.1 38.1±42.5 36.4±30.4 b0.0001
0.1±0.3 0.3±0.5 0.8±1.5 0.3±0.6 0.03
1.1±1.5 3.8±10.0 8.6±22.0 3.1±10.3 NS
MRSA
vs PA
MRSA/PA vs
MSSA/PA
MRSA/PA
vs PA
MSSA/PA vs
MSSA
MSSA/PA
vs PA
b0.0001 0.005 NS 0.0004 b0.0001
b0.0001 0.02 NS 0.0182 b0.0001
NS NS NS NS NS
b0.0001 0.003 NS 0.004 b0.0001
b0.0001 0.008 NS 0.003 b0.0001
NS NS NS NS NS
NS NS NS NS NS
tible Staphylococcus aureus, MRSA: methicillin-resistant Staphylococcus aureus,
rced vital capacity, BMI: Body mass index, IV: intravenous, and NS: non-significant.
ing of the year 2005; IV antibiotic courses and hospitalisations were collected
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Fig. 1. Clinical characteristics of adults and children of the study cohort according to respiratory colonisation with Staphylococcus aureus and Pseudomonas
aeruginosa. * Interaction (Friedman test) across age subgroups was only significant for the number of IV antibiotic courses/year (p=0.02) and the number of days
of IV antibiotic courses/year (p=0.01). Note that black bars represent the same data reported in Table 3.
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whichMRSA andMSSA patients were matched on PA status, age
and gender, nutritional outcomes and FEV1 percent predicted did
not differ in patients with MRSA compared to those with MSSA,Table 4
Yearly decline in FEV1 according to the type of colonisation adjusted for
potential confounders a in reference to patients with neither SA nor PA.
Regression coefficient (%) b 95% CI p value
No SA no PA –
MSSA alone −0.08 −0.16 to +0.00 0.05
MRSA alone −0.08 −0.17 to +0.01 0.08
PA alone −0.07 −0.16 to +0.02 0.11
PA/MSSA −0.05 −0.14 to +0.03 0.22
PA/MRSA −0.11 −0.20 to −0.011 0.03
SA Staphylococcus aureus
PA Pseudomonas aeruginosa
MSSA methicillin-susceptible Staphylococcus aureus
MRSA methicillin-resistant Staphylococcus aureus
PA Pseudomonas aeruginosa
a Age, sex, age at diagnosis, severe genotype (yes/no), and pancreatic insufﬁciency
(yes/no).
b The regression coefﬁcient represents the change in deltaFEV1 (% pred.) relative
to that for subjects with no PA or SA colonisation. The analysis was conducted on
658 patient-years excluding those with Achromobacter xylosoxidans, Burkholderia
cepacia complex and nontuberculous mycobacteria infection.but patients with chronic MRSA were treated more intensely [19].
In a Belgian retrospective case–control study, the MRSA positive
group had more frequent hospitalisations than age- and sex-
matched controls chronically colonised with SA [23].
However, our patients with MRSA/PA appeared more
severely affected than those with MSSA/PA; they had lower
respiratory function (FEV1 49.2% pred. vs 61.9% pred.) and
more IV antibiotic courses. Indeed, patients with MRSA/PA
were similar to those with PA for respiratory function and rate
of antibiotic courses.
In our study, the yearly decline in FEV1 was significantly
larger in MRSA/PA patients than in the comparator group with
no SA/no PA, but this was not the case for patients with MRSA
alone or PA alone. Dasenbrook et al. found that the rate of
FEV1 decline was greater in patients with MRSA than in
patients who were culture-negative for MRSA [10]; however,
the association of MRSA and FEV1 decline was not clinically
significant in adults. On another hand, Sawicki et al. showed that
patients with MRSA displayed a faster decline in lung function
prior to MRSA acquisition and noted that MRSA did not affect
lung function decline [24]; this led the authors to suggest that
MRSA in CF might reflect, rather than cause, greater disease
severity. However, we were not able to demonstrate a higher
prevalence of severe CFTR genotypes in patients colonised with
502 D. Hubert et al. / Journal of Cystic Fibrosis 12 (2013) 497–503MRSA than in patients colonised withMSSA, alone or combined
with PA. Finally, in another single centre study, the FEV1
declines over 2- and 6-year periods were significantly greater in
the chronic MRSA group than in the controls; note that these
patients were not matched for PA status [23].
In most of the studies assessing the consequences of infection
with MRSA and/or MSSA in CF patients, there was no separate
analysis of SA-positive patients according to the presence or
absence of PA, although PA, as well as Burkholderia cepacia
complex, was taken into account in multivariate regression
models [24], FEV1 decline [10] or estimates of survival [11].
We wanted to test whether, in patients with CF, concurrent
colonisation with both SA and PA might have a specific impact.
Consequently, we compared patients with SA only and patients
with both SA and PA, considering MRSA as well as MSSA.
We found that patients with MRSA/PA and PA alone were the
most severe cases, according to their respiratory function, need
for IV antibiotic courses and hospitalisation. FEV1 and FVC
were lower in patients with SA who co-cultured PA than in
patients with SA alone, and this was more marked for MRSA-
positive patients than MSSA-positive patients. Our MSSA/PA
patients were in better clinical condition than PA patients, but this
was not true for MRSA/PA patients. TheMRSA/PA patients also
showed the largest yearly decline in FEV1.
Rosenbluth et al. [25] studied the effects of concurrent
infection with both PA and SA (but without differentiating
MSSA from MRSA) in a cohort of 153 adults with CF. They
showed that such double infections were a significant risk factor
for rapidly declining lung function, although infection either with
PA or withMRSAwas not. In infants and young children, Hudson
et al. reported that patients with PA or SA/PA in their sputa had
worse lung function than patients with SA alone [26]; although SA
alone did not affect survival, patients with SA/PA had a
significantly lower 10-year survival rate than those with either
SA alone or PA alone. The authors concluded that SA and PA
contributed independently and additively to poorer outcomes in
CF. This notion is supported by the analysis of bronchoalveolar
lavage in infants and young children with CF: subjects infected
with SA and PA tend to have more airway inflammation than
subjects infected with PA or SA alone [27]. The independent and
additive effects described for SA on inflammation support the
significance of polymicrobial infection in CF lung disease, but no
information was given about MRSA vs MSSA.
Our study is the first to assess the association of combined
MSSA/PA or MRSA/PA colonisation and the clinical status of
patients with CF including their yearly decline in FEV1. It includes
a large cohort of children and adults and differentiates SA between
MRSA and MSSA. One limitation of our study is that the data
were collected retrospectively. To determine more clearly the
impact of MRSA colonisation on lung function, larger prospective
longitudinal studies are needed, which investigate possible links
between MRSA and PA co-colonisation and clinical outcomes.
In conclusion, the prevalence of MRSA colonisation in our
cohort of CF patients was 17% and corresponds to the peak in
the prevalence in France. The respiratory function of our
patients with MRSA alone was similar to that of children and
adults with MSSA alone. The association of PA and SAworsened the respiratory status of the patients, mainly for patients
with MRSA/PA. These patients co-colonised with MRSA and
PA had the greatest decline in FEV1. Our data suggest that
MRSA in patients with CF may be more deleterious than MSSA
only when associated with PA.
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